Eli Lilly Share Price: LLY Quote, Chart & Forecast

Eli Lilly stock has defied skeptics for four straight years, but the $907-$927 trading range in March-April 2026 puts the pharmaceutical giant at a crossroads between regulatory routine and a $40B obesity opportunity. The stock closed at $927.03 on April 17, 2026, leaving investors to decide whether the dip was a crash buy or the start of a prolonged pullback. This article cuts through the noise to look at what’s driving the volatility and what it means for anyone considering a position.

Current Price: $920.25 · 52-Week High: $1,133.95 · Market Cap: 877.47B · P/E Ratio: 40.39

The table below captures recent trading activity and key milestones that define the current trading range for LLY.

Is Eli Lilly stock a good buy right now?

The answer depends on whether you’re looking at the next six months or the next five years. The recent dip tied to FDA requests for additional safety data on Foundayo created a buying opportunity in the $907-$920 range, yet the stock has bounced back toward $927 after the initial uncertainty faded. For long-term investors, the case rests on a pipeline that the market hasn’t fully priced in yet.

Pros and cons of buying LLY

The implication: The gap between $983 average target and $1,190 high reflects genuine uncertainty about how fast Foundayo can convert prescriptions into recurring revenue.

Analyst price targets

Twenty-four analysts cover Eli Lilly, with price targets ranging from $675 on the low end to $1,190 at the optimistic end, according to Zacks Investment Research. The average target of $983.13 suggests about 27% upside from the $772.87 baseline. Simply Wall St estimates fair value closer to $1,211, with some models pointing toward $1,329 if the company hits its 2026 earnings-per-share target of $39.

Why is Eli Lilly stock crashing?

The word “crash” overstates what happened. Eli Lilly experienced a dip from the $1,074 YTD high down toward $907 in late March 2026 before the FDA’s request for additional safety data on Foundayo added short-term pressure. By mid-April, the stock had recovered to $927.03 as investors digested the regulatory request and separated it from the core approval story.

FDA request for safety data

The FDA approved Foundayo in early April 2026, but simultaneously requested more post-market safety monitoring data from Eli Lilly. This is not unusual for a new drug entering a large patient population, though it created a brief window of uncertainty that some traders used as an exit point. The stock bounced once the market absorbed the distinction between a request for data and a regulatory setback.

Impact on share price

Volume spiked during the March dip, with the stock finding support around $907 before recovering. Technical analysis from StockInvest.us price analysis identified $794.10 as a deeper support level, suggesting the $907-$920 band represented a potential buying zone for investors who believed the regulatory noise was temporary.

Where will Eli Lilly be in 5 years?

Forecasting five years out for any pharma stock requires separating pipeline hope from current fundamentals. Eli Lilly projects revenue of $89.1B and earnings of $34.2B by 2028, with some analysts modeling $123.4B in revenue by 2029 under optimistic scenarios. Whether those numbers hold depends almost entirely on how Foundayo and the broader GLP-1 franchise perform against Novo Nordisk’s established Wegovy.

Stock price forecasts 2026-2030

Simply Wall St models annual revenue growth at 12.7% and EPS growth at 17.1%, with return on equity forecast at 50.2% within three years. If the company achieves its 2026 EPS target of $39 and the market maintains a forward P/E of 34, that would imply a share price around $1,329. More conservative models using the current P/E of 40.39 around a $983 target suggest a flatter trajectory.

Growth drivers

The Foundayo launch is the near-term catalyst. The drug became available April 6, 2026, and initial prescription data through Q2 will either confirm or challenge the market size estimates. Beyond obesity, the $6.3B Centessa acquisition signals serious investment in neuroscience, opening a second growth vector if those programs advance through trials.

What’s the highest Eli Lilly stock has ever been?

Eli Lilly reached $1,133.95 on January 8, 2026 — a record high that came after months of steady gains tied to GLP-1 optimism and ahead of Foundayo’s FDA approval. That peak followed a remarkable climb from $772 at the end of 2024, representing a roughly 47% gain in just over a year.

52-week high context

The 52-week high of $1,133.95 established in early January 2026 came during a period when the obesity drug market was being priced with aggressive assumptions. Analysts had begun upgrading price targets after late 2025 upgrades from Morgan Stanley and Bernstein, and the incoming FDA approval for Foundayo had not yet been fully absorbed by the market. That peak, reached before approval, now serves as a reference point for measuring how far the stock pulled back during the regulatory uncertainty.

Historical peaks

Looking further back, Eli Lilly’s trajectory reflects a company that has reinvented itself several times. Year-end closes tell the story: $276.22 (2021), $365.84 (2022), $582.92 (2023), $772 (2024), and $1,074.68 as the 2025 year-to-date high before the January 2026 peak. The stock has compounded at roughly 45% annually over this stretch, far outpacing the broader pharma sector.

The pattern: Each peak required a fresh catalyst — approval, trial data, or analyst upgrade — suggesting the next leg up will depend on Foundayo prescription numbers rather than narrative alone.

Eli Lilly share price forecast

Analysts are not unanimous, and the spread of price targets reflects genuine disagreement about how much of Eli Lilly’s pipeline is already priced in. The bull case points to Foundayo growth, the Centessa pipeline, and a potential P/E re-rating as earnings accelerate. The bear case centers on competition from Novo Nordisk, regulatory friction, and a valuation that leaves little room for missteps.

Short-term vs long-term outlook

Short-term, the stock faces headwinds from the FDA data request overhang and the broader market’s focus on interest rate sensitivity for growth stocks. The near-term range likely stays between $880 and $1,050 as investors await quarterly prescription updates. Long-term, the consensus skews bullish — 24 analysts averaging $983.13 with upside scenarios extending toward $1,190 to $1,329 depending on Foundayo adoption rates.

Key risks

Novo Nordisk’s Wegovy outperforming Foundayo in head-to-head comparisons represents the most direct competitive risk. If Wegovy maintains better weight-loss efficacy with fewer side effects in real-world use, insurers and prescribers may favor the established product. There’s also the risk that the FDA’s additional safety data requests evolve into formal label changes or usage restrictions that constrain the addressable market. For those interested in cryptocurrency, a Pi Coin Price Selling Guide might offer valuable insights.

The longer view reveals how the stock has moved through key pipeline milestones and market cycles.

Five years of year-end closes show a company that has consistently exceeded expectations, but each leg of the rally required a new catalyst. The current consolidation phase waits for a clear catalyst: Foundayo prescription data.

Clarity on what’s confirmed vs. what’s still unclear

Sorting through the research, some facts are solid while others depend on assumptions the market hasn’t yet validated.

Eli Lilly shares rallied sharply, closing up nearly 3.75%, after the FDA approved Foundayo for obesity treatment.

— Perplexity Finance (Market Analysis Platform)

If the company remains on track to hit its target of $39 in earnings per share and the forward PE multiple remains at 34, then the share price could rise all the way up to $1,329 per share.

— Quiver Quantitative (Financial Data Aggregator)

Summary

Eli Lilly sits at an inflection point where the Foundayo launch could cement its position in the $40B obesity market — or become another revenue stream that fails to live up to the hype. The Q4 2025 revenue surge to $19.3B and institutional upgrades from Morgan Stanley and Bernstein provide a floor of confidence. But the 52-week high of $1,133.95 was set before the stock encountered regulatory friction, and the path back to that level requires concrete prescription data. For investors who believe the GLP-1 market will keep expanding, the current $920 range looks like a reasonable entry. For those who want to see the prescription numbers first, patience may be rewarded or punished depending on what the next earnings report shows.

Related reading: How to Lose Weight Fast: Safe Tips from NHS & Experts · How Much Is My Car Worth – Free Tools and Valuation Guide 2025

Related coverage: live data, charts and forecast fördjupar bilden av Eli Lilly Stock Price – Live Data, Charts and Forecast.

Frequently asked questions